Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinicopathologic Correlation of CD44 + /CD24 − Expression in Breast Cancer: a Report from Tertiary Care Medical University in India

Clinicopathologic Correlation of CD44 + /CD24 − Expression in Breast Cancer: a Report from... CD44 + /CD24 − phenotype has been associated with stem cell-like characteristics with enhanced invasive properties, radiation resistance, and with distinct genetic profiles suggesting a correlation to adverse prognosis in western literature. The aim of this study was to study CD44 + /CD24 − phenotype as an adverse prognostic marker in Indian breast cancer patients. N = 61 breast cancer patients included in a tertiary care facility in India were evaluated for receptor studies (estrogen receptor ER, progesterone receptor PR, Herceptin antibody Her2 neu receptor, CD44 & CD24 stem cell markers). CD44 + /CD24 − phenotype was statistically related to adverse factors like estrogen and progesterone receptors non-expression, her 2 neu expression, and triple-negative breast cancer. Of the 39 patients with ER-ve status, 33 (84.6%) were found to have CD44 + /CD24 − phenotype and 82.5% of all the CD 44 + /CD24 − patients were ER negative (p = 0.001). Thirty-four (75.5%) of the PR-ve patients showed the CD44 + /CD24 − phenotype, and of all the CD 44 + /CD24 − patients, 85% of were PR negative (p = 0.006). Thirty-six (75%) of Her-2-Neu + ve were CD44 + /CD24 − . Approximately 90% of the Her 2 Neu patients expressed CD44 + /CD24 − and 76.9% of all the triple-negative patients were found to be CD44 + /CD24 − expression (p = 0.001). CD44 + /CD24 − had a significant association with adverse prognostic factors like stage of disease, hormonal receptor status, and molecular subtypes in Indian breast cancer patients like the Western data. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Indian Journal of Surgical Oncology Springer Journals

Clinicopathologic Correlation of CD44 + /CD24 − Expression in Breast Cancer: a Report from Tertiary Care Medical University in India

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/clinicopathologic-correlation-of-cd44-cd24-expression-in-breast-cancer-S9frhqhawo

References (21)

Publisher
Springer Journals
Copyright
Copyright © The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
ISSN
0975-7651
eISSN
0976-6952
DOI
10.1007/s13193-022-01649-w
Publisher site
See Article on Publisher Site

Abstract

CD44 + /CD24 − phenotype has been associated with stem cell-like characteristics with enhanced invasive properties, radiation resistance, and with distinct genetic profiles suggesting a correlation to adverse prognosis in western literature. The aim of this study was to study CD44 + /CD24 − phenotype as an adverse prognostic marker in Indian breast cancer patients. N = 61 breast cancer patients included in a tertiary care facility in India were evaluated for receptor studies (estrogen receptor ER, progesterone receptor PR, Herceptin antibody Her2 neu receptor, CD44 & CD24 stem cell markers). CD44 + /CD24 − phenotype was statistically related to adverse factors like estrogen and progesterone receptors non-expression, her 2 neu expression, and triple-negative breast cancer. Of the 39 patients with ER-ve status, 33 (84.6%) were found to have CD44 + /CD24 − phenotype and 82.5% of all the CD 44 + /CD24 − patients were ER negative (p = 0.001). Thirty-four (75.5%) of the PR-ve patients showed the CD44 + /CD24 − phenotype, and of all the CD 44 + /CD24 − patients, 85% of were PR negative (p = 0.006). Thirty-six (75%) of Her-2-Neu + ve were CD44 + /CD24 − . Approximately 90% of the Her 2 Neu patients expressed CD44 + /CD24 − and 76.9% of all the triple-negative patients were found to be CD44 + /CD24 − expression (p = 0.001). CD44 + /CD24 − had a significant association with adverse prognostic factors like stage of disease, hormonal receptor status, and molecular subtypes in Indian breast cancer patients like the Western data.

Journal

Indian Journal of Surgical Oncology – Springer Journals

Published: Mar 1, 2023

Keywords: CD44; CD24; Indian breast cancer; Expression; Chemotherapy response

There are no references for this article.